Cardiff Oncology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Cardiff Oncology şirketinin toplam hissedar öz sermayesi $52.4M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $66.1M ve $13.7M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$60.32m
Eşitlik	US$52.39m
Toplam yükümlülükler	US$13.66m
Toplam varlıklar	US$66.05m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: XE7C 'nin kısa vadeli varlıkları ( $62.2M ) kısa vadeli yükümlülüklerini ( $12.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: XE7C şirketinin kısa vadeli varlıkları ( $62.2M ) uzun vadeli yükümlülüklerini ( $1.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: XE7C borçsuzdur.

Borcun Azaltılması: XE7C un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: XE7C şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: XE7C serbest nakit akışı her yıl % 19.2 1.2 yıl yetecek nakit akışına sahip olacaktır.

Cardiff Oncology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.26 loss per share (vs US$0.25 loss in 2Q 2023)

Cardiff Oncology, Inc. to Report Q2, 2024 Results on Aug 08, 2024

New major risk - Financial position

Insufficient new directors

First quarter 2024 earnings released: US$0.22 loss per share (vs US$0.25 loss in 1Q 2023)

Cardiff Oncology, Inc., Annual General Meeting, Jun 20, 2024

Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study

Full year 2023 earnings released: US$0.93 loss per share (vs US$0.89 loss in FY 2022)

Cardiff Oncology, Inc. Announces First Patient Dosed in Randomized First-Line RAS-Mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Cardiff Oncology, Inc. Provides Clinical Update on Phase 2 Randomized Second-Line ONSEMBLE Trial in Patients with RAS-Mutated mCRC

Cardiff Oncology, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Third quarter 2023 earnings released: US$0.22 loss per share (vs US$0.20 loss in 3Q 2022)

Cardiff Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cardiff Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cardiff Oncology, Inc. Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, Including Single-Agent Activity from Onvansertib Monotherapy

Second quarter 2023 earnings released: US$0.25 loss per share (vs US$0.24 loss in 2Q 2022)

Cardiff Oncology, Inc Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship

First quarter 2023 earnings released: US$0.25 loss per share (vs US$0.25 loss in 1Q 2022)

Full year 2022 earnings released: US$0.89 loss per share (vs US$0.72 loss in FY 2021)

Cardiff Oncology Appoints Fairooz Kabbinavar as Chief Medical Officer

Third quarter 2022 earnings released: US$0.20 loss per share (vs US$0.17 loss in 3Q 2021)

Independent Director recently bought €257k worth of stock

Cardiff Oncology, Inc. Announces Plans for A Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1B/2 Trial in mCRC

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.17 loss in 2Q 2021)

Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from Russell 2000 Value Index

First quarter 2022 earnings released: EPS: US$0 (vs US$0.14 loss in 1Q 2021)

Cardiff Oncology, Inc., Annual General Meeting, Jun 09, 2022

Cardiff Oncology, Inc. Announces Executive Changes

Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.19 loss in 3Q 2020)

Independent Director recently bought €173k worth of stock

Chief Financial Officer recently bought €164k worth of stock

Cardiff Oncology, Inc. Announces New Data from Phase 1B/2 Trial in KRAS-Mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.51 loss in 2Q 2020)

Independent Director Gary Jacob has left the company

Independent Director Thomas Adams has left the company

Cardiff Oncology, Inc. Announces First Patient Dosed in a Phase 2 Trial of Onvansertib in Combination with Irinotecan and 5-FU in Pancreatic Cancer

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.41 loss in 1Q 2020)

Independent Director recently bought €86k worth of stock

Full year 2020 earnings released: US$1.08 loss per share (vs US$2.80 loss in FY 2019)

Revenue beats expectations

New 90-day low: €8.05

Cardiff Oncology, Inc. Updates Data from Its Phase 2 Metastatic Castrate-Resistant Prostate Cancer Trial Were Featured in A Virtual Oral Poster Presentation At the American Society of Clinical Oncology Genitourinary Cancers Symposium

Cardiff Oncology Receives "Study May Proceed" from FDA to Initiate Phase 2 Trial of Onvansertib in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

New 90-day low: €10.10

Cardiff Oncology, Inc. Developing New Treatment Options for Cancer Patients in Indications with the Greatest Medical Need

Cardiff Oncology Presents Data That Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from Its Expanded Access Program

Cardiff Oncology, Inc. Announces Executive Changes

Cardiff Oncology, Inc. Presents Data at ASH Demonstrating the Safety and Anti-Leukemic Activity of Onvansertib in Patients with Relapsed/Refractory AML

Third quarter 2020 earnings released: US$0.19 loss per share

Revenue beats expectations

New 90-day high: €14.00

New 90-day high: €13.60

Cardiff Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $87.75 million.

New 90-day high: €6.95

Cardiff Oncology, Inc. Presents Data At ESMO Confirming Efficacy of Onvansertib and Durability of Response in KRAS-Mutated Metastatic Colorectal Cancer

New 90-day high - €6.05

First half earnings released

New 90-day high - €4.54

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin